Table 1. Characteristics of eligible studies included in the meta-analysis.
| Name | Year | Country | Ethnicity | Cancer type | Sample size | Source | Controls in HWE | Genotyping method | |
| cases/controls | |||||||||
| Hosono [33] | 2013 | Japan | Asian | Endometrial | 91 | 261 | HB | Yes | TaqMan |
| Li [18] | 2013 | China | Asian | Colorectal | 451 | 626 | Mixed | Yes | PCR-RFLP |
| Roszak [17] | 2013 | Poland | Caucasian | Cervical | 446 | 491 | PB | Yes | PCR-HRM |
| Xue [34] | 2013 | China | Asian | Lung | 410 | 410 | HB | Yes | PCR-RFLP |
| Nakao [24] | 2012 | Japan | Asian | Pancreas | 185 | 1465 | HB | No | TaqMan |
| Pan [25] | 2012 | China | Asian | Gastric | 176 | 308 | Mixed | No | MassARRAY |
| Santonocito [19] | 2012 | Italy | Caucasian | Melanoma | 167 | 99 | NM | Yes | PCR-HRM |
| Santos [35] | 2012 | Potugal | Caucasian | Thyroid | 108 | 216 | HB | Yes | TaqMan |
| Wen [32] | 2012 | China | Asian | Gastric | 307 | 307 | Mixed | Yes | MassARRAY |
| Ye [36] | 2012 | China | Asian | Cervical | 539 | 800 | HB | Yes | MA-PCR |
| Yuan [37] | 2012 | China | Asian | Head and neck | 395 | 883 | PB | Yes | TaqMan |
| Zhang [38] | 2012 | China | Asian | Cervical | 80 | 176 | HB | Yes | SNPware 12plex assay |
| Yosunkaya [39] | 2010 | Turkey | Caucasian | Glioma | 119 | 180 | PB | Yes | PCR-RFLP |
| Gao [40] | 2010 | US | Caucasian | Prostate | 453 | 119 | HB | Yes | Sequence |
| Jin [41] | 2010 | Korea | Asian | NHL | 573 | 721 | PB | Yes | PCR-HRM |
| Rajaraman [42] | 2010 | US | Caucasian | Glioma | 340 | 463 | HB | Yes | TaqMan |
| Rajaraman | 2010 | US | Caucasian | Meningioma | 121 | 463 | HB | Yes | TaqMan |
| Rajaraman | 2010 | US | Caucasian | Acoustic neuroma | 65 | 463 | HB | Yes | TaqMan |
| Wang [43] | 2010 | China | Asian | Bladder | 234 | 253 | HB | Yes | PCR-RFLP |
| Liu [44] | 2009 | US | Caucasian | Glioma | 372 | 365 | PB | Yes | MassARRAY |
| McKean [45] | 2009 | US | Caucasian | Glioblastoma | 987 | 1935 | Mixed | Yes | MassARRAY |
| Zhang [46] | 2009 | China | Asian | Gastric | 236 | 320 | HB | Yes | PCR-RFLP |
| Chiang[47] | 2008 | China | Asian | Thyroid | 283 | 469 | HB | Yes | TaqMan |
| Smith[14] | 2008 | US | Caucasian | Breast | 314 | 397 | HB | Yes | MassARRAY |
| Berndt[48] | 2007 | US | Caucasian | Colorectal | 649 | 659 | NM | Yes | TaqMan |
| Cao[49] | 2007 | France | Caucasian | Breast | 83 | 100 | HB | Yes | Sequence |
| Figueroa[50] | 2007 | Spain | Caucasian | Bladder | 1138 | 1131 | HB | Yes | TaqMan |
| Li[51] | 2007 | US | Caucasian | Head and neck | 830 | 854 | HB | Yes | PCR-RFLP |
| Stern[52] | 2007 | Singapore | Asian | Colorectal | 307 | 1173 | PB | Yes | TaqMan |
| Landi[53] | 2006 | Multiple regions | Caucasian | Lung | 292 | 307 | HB | Yes | APEX |
| Li[54] | 2006 | US | Caucasian | Melanoma | 602 | 603 | HB | Yes | PCR-RFLP |
| Miao[15] | 2006 | China | Asian | Gastric | 500 | 1000 | PB | No | PCR-RFLP |
| Shen[55] | 2006 | US | Caucasian | NHL | 455 | 535 | PB | Yes | TaqMan |
| Wu[56] | 2006 | US | Caucasian | Bladder | 606 | 595 | HB | Yes | TaqMan |
| Zhai[57] | 2006 | China | Asian | Breast | 302 | 639 | HB | Yes | PCR-RFLP |
| Zhang[58] | 2006 | US | Caucasian | Breast | 1715 | 1371 | PB | Yes | TaqMan |
| Zhang[16] | 2005 | China | Asian | Lung | 1000 | 1000 | HB | Yes | PCR-RFLP |
| Hao[59] | 2004 | China | Asian | Esophageal | 414 | 479 | HB | Yes | PCR-RFLP |
| Lockett[5] | 2004 | US | Caucasian | Prostate | 438 | 427 | HB | Yes | MassARRAY |
PB: population-based; HB: hospital-based; HWE: Hardy-Winberg equilibrium. Genotyping method: PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; MassARRAY: genotyping was performed using the Sequenom MassARRAY iPLEXTM platform2. MassARRAY Workstation version 3.3 software was used to process and analyze iPLEX SpectroCHIP bioarrays; PCR-HRM, PCR cycling and high resolution melting analysis was performed on the Rotor-Gene 6000TM. APEX: polymorphism was analyzed together for a given sample by a microarray technique based on the arrayed primer extension principle.